Skip to main content

Generics

  • Court rules in favor of Watson in generic Fentora patent suit

    MORRISTOWN, N.J. — A generic painkiller made by Watson Pharmaceuticals does not infringe on the patent covering the branded version, a U.S. District Court has ruled.

    Watson said the U.S. District Court for the District of Delaware ruled that Watson’s generic version of Cephalon’s Fentora (fentanyl buccal tablets) does not infringe on two patents that were set to expire in March 2019, according to Food and Drug Administration records.

  • Senators to FDA: Stop delaying generic drug approvals

    WASHINGTON — Five senators have issued a letter to Food and Drug Administration commissioner Margaret Hamburg to expand Americans' access to affordable medications by avoiding the delay of generic drug approvals.

  • Study: $4 generic programs could help save society close to $6 billion

    PITTSBURGH — Patients that opt to fill their prescriptions through a $4 generic program could help garner societal savings of nearly $6 billion, a new study found.

  • PTCB's CREST Summit emphasized pharmacy's role in health care

    WASHINGTON — By 2015, “pharmacists will be the healthcare professionals responsible for providing patient care that ensures optimal medication therapy outcomes.” That was the consensus reached in the Joint Commission of Pharmacy Practitioners' vision statement at the Pharmacy Technician Certification Board’s Consumer Awareness, Resources, Education, State Policy and Testing Summit last month.

  • '60 Minutes' examines counterfeit drug problem

    NEW YORK — "Fake drugs are a big threat and an exploding threat," Kumar Kibble, deputy director of Immigration and Customs Enforcement, told the news program "60 Minutes" in a segment that appeared Sunday night.

  • Under PEPFAR, Matrix Labs gets OK to sell zidovudine tablets

    PITTSBURGH — A subsidiary of Mylan has won approval to sell a generic drug for HIV and AIDS in developing countries under the President’s Emergency Plan for AIDS Relief.

    Mylan announced Thursday that Matrix Labs won Food and Drug Administration approval for zidovudine tablets in the 100-mg strength. The drug is a generic version of ViiV Healthcare’s Retrovir, an antiretroviral sold as a water-dispersible tablet. The drug is designed to treat HIV and AIDS in children and prevent transmission of the virus from pregnant mothers to their children.

  • Hospira gets OK to market generic Taxotere

    LAKE FOREST, Ill. — Hospira has received approval from the Food and Drug Administration for a generic cancer treatment.

    Hospira will offer 20-mg, 80-mg and 160-mg vials of docetaxel at a 10-mg/mL concentration. Docetaxel is a generic version of Sanofi-Aventis's Taxotere.

    Hospira already markets docetaxel in Europe and Australia, the drug maker noted.

  • Watson promotes two SVPs

    MORRISTOWN, N.J. — Generic drug maker Watson Pharmaceuticals has promoted two executives to EVP, the company said Wednesday.

    The company gave the promotions to SVP, general counsel and secretary David Buchen and SVP and CFO R. Todd Joyce. Both will continue to report to CEO Paul Bisaro.

X
This ad will auto-close in 10 seconds